Economic study

New health economic study proves the value of CADScor® in

Press release
Malmö, Sweden, September 7, 2021

New economic health study proves the value of CADScor® in coronary disease Diagnostic

A peer reviewed publication in the September 2021 montageIsure of PharmacoEconomics shows a valued £12.3m savings to the health english care system per 100,000 eligible patients when using the Acarix CADScor system to adjust yourselfyou coronary artery disease (CAD).

Coronary artery disease (CAD) is the most common heart and circulatory disease and the leading cause of death worldwide. The current diagnostic pathway for coronary artery disease is expensive, time consuming and for up to 90% of patients testing is unnecessary.

The Acarix CADScor System is a CE and FDA cleared device to enable highly accurate early removal of CAD using acoustic detection before patients undergo invasive diagnostic procedures.

The authors assessed the cost-utility of the CADScor system for excluding coronary artery disease at an early stage from the diagnostic testing pathway in England. The results indicate cost savings of £131 per patient over a one-year horizon. The conclusion is that when initiated prior to using current standard tests such as computed tomography coronary angiography, CADScor® test cost reduction for the health service over different time horizons.

“Today, many patients at intermediate risk for coronary artery disease are referred for expensive, time-consuming and even invasive diagnostic tests. These independent health economic outcomes show great potential for reducing costs and workload and increasing the focus of resources on patients who really need them. Our technology effectively excludes people who do not have coronary artery disease. Only 6-10% of the population with chronic chest pain is diagnosed with coronary artery disease. With CADScor®exclusion can be done accurately, quickly and cost-effectively,” says Per Persson, CEO of Acarix.

Find the article here.

For more information, please contact:
Per Persson, CEO, Email: [email protected], Phone: +46 73 600 59 90

The information has been released for public disclosure, through the Contact nobody agency above September 72021, to 14.00 HEC.

About Acarix:
Acarix was founded in 2009 and is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX). Acarix’s CADScor system uses an advanced sensor placed on the skin above the heart to listen for sounds of heart contraction motion and turbulent flow. It was designed to be an all-in-one system in the sense that the cardiac signal will be recorded, processed and displayed as a patient specific score, the CAD score, on the device screen. The reading is obtained in less than 10 minutes. Safe and suitable for use in outpatient and hospital settings, the CADScor system therefore has the potential to play a major role in patient triage, saving many patients from having to undergo stressful invasive diagnostic procedures. Redeye AB (+46 (0)8 121 576 90, [email protected]) is Certified Adviser of Acarix. For more information, visit

  • Acarix_PR_CADScor HEOR publication_ENG.